These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 11906286

  • 1. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
    Shim JY, Welsh WJ, Cartier E, Edwards JL, Howlett AC.
    J Med Chem; 2002 Mar 28; 45(7):1447-59. PubMed ID: 11906286
    [Abstract] [Full Text] [Related]

  • 2. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
    Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH, Nie J, Lewis D, Reggio PH.
    Mol Pharmacol; 2002 Dec 28; 62(6):1274-87. PubMed ID: 12435794
    [Abstract] [Full Text] [Related]

  • 3. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP, Kraichely DM, Wilken GH, Howlett AC.
    Biochem Pharmacol; 2000 Nov 01; 60(9):1315-23. PubMed ID: 11008125
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716).
    Francisco ME, Seltzman HH, Gilliam AF, Mitchell RA, Rider SL, Pertwee RG, Stevenson LA, Thomas BF.
    J Med Chem; 2002 Jun 20; 45(13):2708-19. PubMed ID: 12061874
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
    Terranova JP, Michaud JC, Le Fur G, Soubrié P.
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov 20; 352(5):576-9. PubMed ID: 8751088
    [Abstract] [Full Text] [Related]

  • 6. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
    McCollum L, Howlett AC, Mukhopadhyay S.
    J Pharmacol Exp Ther; 2007 Jun 20; 321(3):930-7. PubMed ID: 17379772
    [Abstract] [Full Text] [Related]

  • 7. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.
    Hurst D, Umejiego U, Lynch D, Seltzman H, Hyatt S, Roche M, McAllister S, Fleischer D, Kapur A, Abood M, Shi S, Jones J, Lewis D, Reggio P.
    J Med Chem; 2006 Oct 05; 49(20):5969-87. PubMed ID: 17004712
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis.
    Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlágh B.
    J Neurosci; 2005 Mar 16; 25(11):2874-84. PubMed ID: 15772347
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.
    Ihenetu K, Molleman A, Parsons ME, Whelan CJ.
    Eur J Pharmacol; 2003 Jan 01; 458(1-2):207-15. PubMed ID: 12498928
    [Abstract] [Full Text] [Related]

  • 11. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
    Petitet F, Jeantaud B, Capet M, Doble A.
    Biochem Pharmacol; 1997 Dec 01; 54(11):1267-70. PubMed ID: 9416978
    [Abstract] [Full Text] [Related]

  • 12. Inhibitory effects of SR141716A on G-protein activation in rat brain.
    Sim-Selley LJ, Brunk LK, Selley DE.
    Eur J Pharmacol; 2001 Mar 02; 414(2-3):135-43. PubMed ID: 11239913
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE.
    Mol Pharmacol; 2006 Jul 02; 70(1):41-50. PubMed ID: 16571654
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
    Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, Casti P, Vargiu R, Pani L.
    J Pharmacol Exp Ther; 2003 Jul 02; 306(1):363-70. PubMed ID: 12663689
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain.
    Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O.
    Pharmacology; 2006 Jul 02; 76(4):157-62. PubMed ID: 16446560
    [Abstract] [Full Text] [Related]

  • 20. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
    Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A.
    J Med Chem; 1999 Feb 25; 42(4):769-76. PubMed ID: 10052983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.